Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aeterna Zentaris and Keryx Biopharmaceuticals have announced the termination of license agreement related to perifosine, Akt inhibitor anticancer compound.
Subscribe to our email newsletter
With the termination of the agreement, Aeterna has regained the North American rights to perifosine, in all indications.
Aeterna announced the continuation of the ongoing Phase 3 trial in multiple myeloma with perifosine.
Aeterna Zentaris president and CEO Juergen Engel said, "Our decision to continue the Phase 3 trial in multiple myeloma is based first and foremost on the existing solid preclinical and clinical data, and on the support for this drug among key opinion leaders in this field."
According to the agreement, intellectual property and development data, such as INDs and orphan drug designations on perifosine were shifted to Aeterna.
Keryx is eligible to receive low single-digit royalties on future net sales of perifosine in North America from Aeterna.